Display options
Cite
Francis JC, Capper A, Ning J, et al. . Oncotarget. 2018;9(7):7604-7615doi: 10.18632/oncotarget.24123.
Francis, J. C., Capper, A., Ning, J., Knight, E., de Bono, J., & Swain, A. (2018). . Oncotarget, 9(7), 7604-7615. https://doi.org/10.18632/oncotarget.24123
Francis, Jeffrey C, et al. "." Oncotarget vol. 9,7 (2018): 7604-7615. doi: https://doi.org/10.18632/oncotarget.24123
Francis JC, Capper A, Ning J, Knight E, de Bono J, Swain A. . Oncotarget. 2018 Jan 10;9(7):7604-7615. doi: 10.18632/oncotarget.24123. eCollection 2018 Jan 26. PMID: 29484136; PMCID: PMC5800928.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Jan 10;9(7):7604-7615. doi: 10.18632/oncotarget.24123. eCollection 2018 Jan 26.

[No title available]

Oncotarget

Jeffrey C Francis, Amy Capper, Jian Ning, Eleanor Knight, Johann de Bono, Amanda Swain

Affiliations

  1. Division of Cancer Biology, The Institute of Cancer Research, London SW3 6JB, UK.
  2. Tumour Profiling Unit, The Institute of Cancer Research, London SW3 6JB, UK.
  3. Division of Clinical Studies, The Institute of Cancer Research, London SM2 5NG, UK.

PMID: 29484136 PMCID: PMC5800928 DOI: 10.18632/oncotarget.24123

Abstract

Aggressive lethal prostate cancer is characterised by tumour invasion, metastasis and androgen resistance. Understanding the mechanisms by which localised disease progresses to advanced lethal stages is key to the development of effective therapies. Here we have identified a novel role for the transcription factor, SOX9, as a driver of aggressive invasive prostate cancer. Using genetically modified mouse models, we show that increased

Keywords: aggressive invasive prostate cancer; cell lineage plasticity; epithelial to mesenchymal transition; prostate cancer mouse models

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare no conflicts of interest.

References

  1. Dev Biol. 2008 Apr 15;316(2):302-11 - PubMed
  2. Genesis. 2002 Feb;32(2):148-9 - PubMed
  3. Cell Adh Migr. 2014;8(1):29-35 - PubMed
  4. Cancer Cell. 2003 Sep;4(3):209-21 - PubMed
  5. J Clin Invest. 2013 Mar;123(3):1109-22 - PubMed
  6. Oncotarget. 2012 Jun;3(6):651-63 - PubMed
  7. Nature. 2013 Sep 19;501(7467):328-37 - PubMed
  8. Cancer Res. 2004 Mar 15;64(6):2270-305 - PubMed
  9. Urol Oncol. 2017 Aug;35(8):535 - PubMed
  10. Nature. 2011 Feb 10;470(7333):269-73 - PubMed
  11. Lancet. 2016 Jan 2;387(10013):70-82 - PubMed
  12. Cell. 2008 Oct 3;135(1):137-48 - PubMed
  13. Mech Dev. 2001 Mar;101(1-2):61-9 - PubMed
  14. Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96 - PubMed
  15. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1563-8 - PubMed
  16. Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):E6544-52 - PubMed
  17. Dev Cell. 2005 Feb;8(2):179-92 - PubMed
  18. Nat Med. 2013 Aug;19(8):1023-9 - PubMed
  19. Cancer Res. 1998 Jan 15;58(2):204-9 - PubMed
  20. Cell Stem Cell. 2015 Jul 2;17 (1):60-73 - PubMed
  21. Science. 2017 Jan 6;355(6320):84-88 - PubMed
  22. Cancer Res. 2010 Feb 1;70(3):979-87 - PubMed
  23. Nature. 2005 Aug 4;436(7051):725-30 - PubMed
  24. Science. 2017 Jan 6;355(6320):78-83 - PubMed
  25. Cancer Res. 2007 Jan 15;67(2):528-36 - PubMed
  26. Nat Genet. 2013 Jul;45(7):739-746 - PubMed
  27. Nat Commun. 2016 Feb 29;7:10798 - PubMed
  28. Cell. 2012 Mar 2;148(5):1015-28 - PubMed
  29. Cancer Res. 2012 Mar 1;72(5):1301-15 - PubMed

Publication Types

Grant support